



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	10/669,778
Filing Date	September 24, 2003
First Named Inventor	Michael R. LEADBETTER
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	P-088-US3

U.S. PATENT DOCUMENTS

Class / Subclass

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
JRL	A1	US-4,643,987	02-17-1987	Nagarajan et al.	514 / 8
JRL	A2	US-4,698,327	10-06-1987	Nagarajan et al.	514 / 8
JRL	A3	US-4,727,064	02-23-1988	Pitha	514 / 58
JRL	A4	US-4,983,586	01-08-1991	Bodor	514 / 58
JRL	A5	US-5,024,998	06-18-1991	Bodor	514 / 58
JRL	A6	US-5,591,714	01-07-1997	Nagarajan et al.	514 / 9
JRL	A7	US-5,602,112	02-11-1997	Rubinfeld	514 / 58
JRL	A8	US-5,750,509	05-12-1998	Malabarba et al.	514 / 11
JRL	A9	US-5,840,684	11-24-1998	Cooper et al.	514 / 11
JRL	A10	US-5,916,873	06-29-1999	Cooper et al.	514 / 9
JRL	A11	US-6,323,176 B1	11-27-2001	Jamison et al.	514 / 7
JRL	A12	US-6,392,012 B1	05-21-2002	Judice et al.	530 / 317

FOREIGN PATENT DOCUMENTS

Class / Subclass

Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
JRL	B1	WO 94/12217	06-09-1994	Insite Vision Inc.	—	
JRL	B2	WO 00/04044	01-27-2000	Princeton University	—	
JRL	B3	WO 00/39156	07-06-2000	Advanced Medicine, Inc.	—	
JRL	B4	WO 00/54751 (in German with English abstract)	09-21-2000	BASF Aktiengesellschaft	—	
JRL	B5	WO 00/59528	10-12-2000	Trustees of Princeton University	—	
JRL	B6	WO 01/83520 A2	11-08-2001	Advanced Medicine, Inc.	—	
JRL	B7	WO 01/97851 A2	12-27-2001	Cubist Pharmaceuticals, Inc.	—	
JRL	B8	WO 01/98326 A2	12-27-2001	Advanced Medicine, Inc.	—	
JRL	B9	WO 01/98327 A2	12-27-2001	Advanced Medicine, Inc.	—	
JRL	B10	WO 01/98329 A1	12-27-2001	Advanced Medicine, Inc.	—	
JRL	B11	EP 0 667 353 A1	08-16-1995	Eli Lilly and Company	—	
JRL	B12	EP 0 816 378 A1	01-07-1998	Eli Lilly and Company	—	
JRL	B13	JP 2000-302687 (in Japanese with English translation)	10-31-2000	Sagami Chemical Research Center	—	X

Examiner Signature	Jeffrey B. Russel	Date Considered	June 16, 2004
--------------------	-------------------	-----------------	---------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08b(05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	10/669,778
Filing Date	September 24, 2003
First Named Inventor	Michael R. LEADBETTER
Group Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	P-088-US3

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
JR	C1	ALLEN et al., "The Role of Hydrophobic Side Chains as Determinants of Antibacterial Activity of Semisynthetic Glycopeptide Antibiotics", The Journal of Antibiotics, Vol. 50, No. 8, pp 677-684 (1997)	
JR	C2	GE et al., "Vancomycin Derivatives That Inhibit Peptidoglycan Biosynthesis Without Binding D-Ala-D-Ala", Science, Vol. 284, pp 507-511 (1999)	
JR	C3	MALABARBA et al., "New Semisynthetic Glycopeptides MDL 63,246 and MDL 63,042, and Other Amide Derivatives of Antibiotic A-40, 926 Active against Highly Glycopeptide-resistant VanA Enterococci", The Journal of Antibiotics, Vol. 48, No. 8, pp 869-883 (1995)	
JR	C4	NAGARAJAN et al., "Synthesis and Antibacterial Evaluation of N-Alkyl Vancomycins", The Journal of Antibiotics, Vol. XLII, No. 1, pp 63-72 (1989)	
JR	C5	NICOLAOU et al., "Chemistry, Biology and Medicine of the Glycopeptide Antibiotics", Angew. Chem. Int. Ed., Vol. 38, pp 2097-2152 (1999)	
JR	C6	PAVLOV et al., "A New Type of Chemical Modification of Glycopeptides Antibiotics: Aminomethylated Derivatives of Eremomycin and Their Antibacterial Activity", The Journal of Antibiotics, Vol. 50, No. 6, pp 509-513 (1997)	
JR	C7	PAVLOV et al., "Chemical Modification of Glycopeptide Antibiotics [VC1]", Russian Journal of Bioorganic Chemistry, Vol. 24, No. 9, pp 570-587 (1998)	
JR	C8	PAVLOV et al., "Mono and Double Modified Teicoplanin Aglycon Derivatives on the Amino Acid No. 7: Structure-activity Relationship", The Journal of Antibiotics, Vol. 51, No. 1, pp 73-78 (1998)	
JR	C9	ZHANG et al., "A review of recent applications of cyclodextrins for drug discovery", Expert Opinion on Therapeutic Patents, Vol. 9, No. 12, 21 pages (1999)	

Examiner Signature	Jeffrey E. Russel	Date Considered	June 16, 2004
-----------------------	-------------------	--------------------	---------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.